Clene seeks FDA accelerated approval for CNM-Au8 in ALS

CLNN•2026-10-19

Clene submitted an FDA application in October 2026 seeking accelerated approval of CNM-Au8 for amyotrophic lateral sclerosis, based on neurofilament light chain biomarker data and clinical outcomes.

Clene seeks FDA accelerated approval for CNM-Au8 in ALS

1. FDA application

Related News

FibroBiologics cell therapy preserves disc height in preclinical rabbit study

H.B. Fuller board rejects second proposal for building adhesive solutions segment

Prysmian completes acquisition of Atkore

Klarna expands Fiserv partnership to enterprise merchants

Bitmine says crypto price declines offer attractive risk-reward opportunities